GLUCAGON-LIKE PEPTIDE-1 (GLP-1) AGONISTS MARKET - GROWTH, TRENDS, COVID-19 IMPACT, AND FORECASTS (2022 - 2027)

GLUCAGON-LIKE PEPTIDE-1 (GLP-1) AGONISTS MARKET - GROWTH, TRENDS, COVID-19 IMPACT, AND FORECASTS (2022 - 2027)

The Glucagon-like Peptide-1 (GLP-1) Agonists Market is set to witness a CAGR of more than 2%, during the forecast period. The market is estimated to reach a value of about USD 13 billion by 2027.

The COVID-19 pandemic positively impacted the Glucagon-like Peptide-1 (GLP-1) Agonists Market. Diabetes and uncontrolled hyperglycemia are risk factors for poor outcomes in patients with COVID-19 including an increased risk of severe illness or death. People with diabetes have a weaker immune system, the COVID-19 complication aggravates the condition, and the immune system gets weaker very fast. People with diabetes have more chances to get into serious complications rather than normal people.

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a class of medications used for the treatment of type 2 diabetes and some drugs are also approved for obesity. One of the benefits of this class of drugs over older insulin secretagogues, such as sulfonylureas or meglitinides, is that they have a lower risk of causing hypoglycemia. Besides being important glucose-lowering agents, GLP-1RAs have significant anti-inflammatory and pulmonary protective effects and an advantageous impact on gut microbes’ composition. Therefore, GLP-1RAs have been potential candidates for treating patients affected by COVID-19 infection, with or even without type 2 diabetes, as well as excellent antidiabetic (glucose-lowering) agents during COVID-19 pandemic times.

According to International Diabetes Federation (IDF), the adult diabetes population in 2021 is approximately 537 million, and this number is going to increase by 643 million in 2030. Technological advancements have increased over the period leading to several modifications either in the GLP-1RA drug or the formulations being developed.

Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.

Key Market TrendsDulaglutide Segment Occupied the Highest Market Share in the Glucagon-like Peptide-1 (GLP-1) Agonists Market in 2021

Dulaglutide drug held the highest share in 2021, with a revenue of more than USD 5 billion in the Glucagon-like Peptide-1 (GLP-1) Agonists Market.

GLP1RAs have been available internationally and are now recommended for use when escalation of treatment for type 2 diabetes is required after metformin and lifestyle management. They can be safely used with all other glucose-lowering therapies except vildagliptin. Dulaglutide (Trulicity) is a weekly subcutaneous GLP1RA that is highly effective for reducing HbA1c with additional weight loss and cardiorenal protection benefits. Therapy with dulaglutide allows many patients to reach and maintain target HbA1c without insulin and/or sulfonylureas, eliminating the associated hypoglycemia risk. GLP1RAs elicit greater weight reduction and are recommended over SLGT2 inhibitors when cerebrovascular disease other than heart failure or renal disease predominates.

Dulaglutide is fully funded for patients meeting special authority criteria in some countries. For instance, New Zealand guidelines recommend offering GLP1RAs to all patients with HbA1c levels above target, especially when GLP1RA use would provide additional reductions in cardiovascular risk and/or permit reduction or cessation of other therapies that contribute to weight gain or hypoglycemia.

Owing to the rising rate of obesity, growing genetic factors for type-2 diabetes, and the increasing prevalence it is likely that the market will continue to grow.

North America is Expected to Dominate the Glucagon-like Peptide-1 (GLP-1) Agonists Market in Terms of Revenue

North America holds the highest market share in the Glucagon-like Peptide-1 (GLP-1) Agonists Market and is also expected to register a CAGR of more than 2% in the forecast period.

Health Canada is the third regulatory agency to provide more options for people interested in GLP-1 agonists after it approved the first and only GLP-1 agonist pill (Rybelsus by NovoNordisk) for people with type 2 diabetes in 2020 after approval by the European Medicines Agency and the approval in the US in 2019. GLP-1 RAs can be taken alone or in combination with other treatments for type 2 diabetes to improve blood glucose management, i.e., time in range, in addition to lowering blood glucose, they benefit heart health by reducing the risk of heart attack, stroke, and heart-related death. This is important because people with type 2 diabetes are at substantially higher risk of heart disease than those without diabetes.

North America has a high prevalence of diabetes because of the sedentary lifestyle and due to which the market is expected to grow during the forecast period.

Competitive Landscape

The GLP-1 market is consolidated, with four major manufacturers namely Eli Lilly, Sanofi, Novo Nordisk, and AstraZeneca holding a presence in all regions. Currently, no generic versions of the GLP-1s are available in the market since the drugs are patent protected.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.